Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 9.77M P/E - EPS this Y -110.00% Ern Qtrly Grth -
Income -3.59M Forward P/E -0.34 EPS next Y 25.80% 50D Avg Chg -12.00%
Sales 12.04M PEG - EPS past 5Y - 200D Avg Chg -70.00%
Dividend N/A Price/Book N/A EPS next 5Y - 52W High Chg -84.00%
Recommedations 2.30 Quick Ratio 0.84 Shares Outstanding 2.28M 52W Low Chg 41.00%
Insider Own 2.60% ROA -29.16% Shares Float 2.08M Beta 1.04
Inst Own 11.71% ROE - Shares Shorted/Prior 24.41K/94.86K Price 0.37
Gross Margin -1.93% Profit Margin -29.79% Avg. Volume 315,669 Target Price 37.50
Oper. Margin 13.37% Earnings Date May 8 Volume 3,392,375 Change 14.06%
About TRACON Pharmaceuticals, Inc.

TRACON Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel targeted therapeutics for cancer in the United States. Its clinical stage products include envafolimab (KN035), a PD-L1 single-domain antibody for the treatment of refractory soft tissue sarcoma; and YH001, an investigational humanized cytotoxic T-lymphocyte-associated protein 4 IgG1 monoclonal antibody that is in Phase I clinical trial for the treatment of various cancer indications. The company's clinical stage products also include TRC102, a small molecule that is in Phase II clinical trial for the treatment of mesothelioma, and in Phase I clinical trial to treat solid tumors, lung cancer, and glioblastoma; and TJ004309, a CD73 antibody that is in Phase I clinical development for the treatment of solid tumors. In addition, it is developing bispecific antibodies, which are in preclinical stage. It has collaboration and license agreements with 3D Medicines Co., Ltd. and Jiangsu Alphamab Biopharmaceuticals Co., Ltd. for the development of envafolimab; I-Mab Biopharma for the development of CD73 antibody TJ004309 and bispecific antibodies; and cooperative research and development agreement with National Cancer Institute. The company was formerly known as Lexington Pharmaceuticals, Inc. and changed its name to TRACON Pharmaceuticals, Inc. in March 2005. TRACON Pharmaceuticals, Inc. was incorporated in 2004 and is headquartered in San Diego, California.

TRACON Pharmaceuticals, Inc. News
04/10/24 Wall Street Favorites: 3 Penny Stocks With Strong Buy Ratings for April 2024
04/08/24 TRACON Pharmaceuticals Announces Reverse Stock Split
04/03/24 TRACON Pharmaceuticals Provides Update on Ongoing ENVASARC Phase 2 Pivotal Trial Following Independent Data Monitoring Committee Recommendation to Continue the Trial as Planned
03/07/24 TRACON Pharmaceuticals, Inc. (NASDAQ:TCON) Q4 2023 Earnings Call Transcript
03/05/24 TRACON Pharmaceuticals Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update
02/28/24 TRACON to Report Fourth Quarter and Year-End 2023 Financial Results and Provide Corporate Update on March 5, 2024
12/20/23 TRACON Pharmaceuticals Provides Positive Update on Ongoing ENVASARC Pivotal Phase 2 Trial
11/21/23 Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
11/20/23 TRACON Pharmaceuticals Announces License of Product Development Platform for $3.0 Million Upfront Payment
11/12/23 TRACON Pharmaceuticals, Inc. (NASDAQ:TCON) Q3 2023 Earnings Call Transcript
11/09/23 TRACON Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update
10/31/23 TRACON to Report Third Quarter 2023 Financial Results and Provide Corporate Update on November 9, 2023
09/18/23 TRACON Pharmaceuticals Announces ENVASARC Phase 2 Pivotal Trial Exceeded Futility Threshold at Final Interim Analysis and Will Continue as Planned
09/05/23 TRACON Pharmaceuticals Announces Participation at Upcoming Investor Conferences
08/25/23 7 F-Rated Biotech Stocks You Shouldn’t Touch With a 10-Foot Pole
08/15/23 Q2 2023 TRACON Pharmaceuticals Inc Earnings Call
08/14/23 TRACON Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate Update
03:05 PM TRACON to Report Second Quarter 2023 Financial Results and Provide Corporate Update on August 14, 2023
07/11/23 TRACON Pharmaceuticals Announces Collection of Arbitration Award from I-Mab Biopharma
06/20/23 TRACON Pharmaceuticals Announces Positive Results Based on Ongoing Double-Digit Objective Response Rate for Single Agent Envafolimab in the ENVASARC Phase 2 Pivotal Trial
TCON Chatroom

User Image ChiefOG Posted - 2 hours ago

$TCON 🧐

User Image DaveW_4U Posted - 10 hours ago

$TCON little bump after hours. no volume but could it be a little forecast for the future?

User Image ieatbaguette Posted - 17 hours ago

$TAOP bids coming.in $ZVSA $TCON

User Image RollingDollar Posted - 17 hours ago

$TCON

User Image RollingDollar Posted - 17 hours ago

$TCON

User Image dddanielek Posted - 04/30/24

$TCON strange algos.

User Image DaveW_4U Posted - 04/30/24

$TCON bought 18k+ shares at close

User Image Hereinbama35 Posted - 04/30/24

$TCON Down 80% in the past month? What y’all crazy people doing here?? 😳

User Image AshTrade_ Posted - 04/30/24

$TCON Added heavy till it pop

User Image BobBuran Posted - 04/30/24

Tuesday Dow opens -134 and we open -$7,035 Bad: $NXL $TCON $HOLO Good: $MTC $JANX #stocks

User Image User555 Posted - 04/30/24

$TCON what happened??

User Image saud89 Posted - 04/29/24

$TCON I entered at a good price of $2 ??

User Image somaopp Posted - 04/29/24

$TCON low vol. pump in progress, not sure why?

User Image RollingDollar Posted - 04/29/24

$TCON

User Image Respectable_Level Posted - 04/29/24

$TCON Did this Reverse split?

User Image RollingDollar Posted - 04/26/24

$TCON

User Image Naif777 Posted - 04/26/24

$TCON

User Image StocksMilkShake Posted - 04/25/24

$TCON This is so quiet but... one day . They will chase this to $3+ $PCSA $AIRE $AGBA

User Image Michelleinvestor Posted - 04/23/24

$TCON take a look at $sls this week. Big news incoming in one week or less!

User Image StocksMilkShake Posted - 04/23/24

$CZOO $NKGN $NIVF $TCON BREAKOUT ✌❤💥💥💥

User Image StocksMilkShake Posted - 04/23/24

$OPRT $TCON $NKGN $NIVF

User Image Abjo Posted - 04/23/24

$TCON Might add more down here

User Image Hate_1987 Posted - 04/22/24

$TCON

User Image jctataio Posted - 04/22/24

$MTTR $PHGE $EBS $TCON 🔥🔥🚨🚨

User Image Radcon2017 Posted - 04/22/24

$TCON Is TCON in danger of being delisted?… Their market cap is around $4 million, how do they keep meeting Nasdaq Requirements…Also they just completed a Reverse Split, but if they fall below $1, would they have to do another Reverse Split?…Share price not looking good in my opinion…

User Image 2brad2 Posted - 04/19/24

$TCON under $2 by the end of the week lol. Boy that was hard to predict 💩

User Image Michelleinvestor Posted - 04/19/24

$TCON get your $sls lottery ticket before it is too late. See article https://seekingalpha.com/article/4684757-sellas-life-sciences-group-a-lottery-ticket-with-an-estimated-9x-payout

User Image StocksMilkShake Posted - 04/18/24

$TCON 💥Z E R O DEBT 💥FLOAT 2M . Price Target as per yahoo finance $37.50 . Cash runway till 3rd quarter of 2024 . Pirpeline 1-PH3 💥 4-PH2 💥 7-PH1 👆💥👍✌ $HOLO $TIRX $BPTH

User Image Billionscash Posted - 04/18/24

$TCON

User Image Billionscash Posted - 04/18/24

$TCON

Analyst Ratings
HC Wainwright & Co. Buy Apr 3, 24
HC Wainwright & Co. Buy Mar 6, 24
HC Wainwright & Co. Buy Nov 20, 23
JonesTrading Hold Aug 21, 23
Baird Outperform Aug 15, 23
Maxim Group Buy May 11, 23
Baird Outperform May 11, 23
HC Wainwright & Co. Buy Mar 9, 23
Baird Outperform Feb 23, 22
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
THEUER CHARLES President and CEO President and CEO Apr 26 Buy 0.71 50,999 36,209 399,417 04/28/23
THEUER CHARLES President and CEO President and CEO Feb 28 Buy 1.52 5,000 7,600 344,918 03/02/23
THEUER CHARLES President and CEO President and CEO Jan 18 Buy 1.62 6,800 11,016 339,918 01/19/23
LARUE WILLIAM R Director Director Dec 21 Sell 1.2553 120 151 7,763 01/19/23
Brown Scott B. Chief Financial Offi.. Chief Financial Officer Dec 29 Buy 1.49 3,500 5,215 21,628 01/03/23
Opaleye Management Inc. 10% Owner 10% Owner Dec 14 Buy 1.25 167,500 209,375 440,000 12/16/22
THEUER CHARLES President and CEO President and CEO Dec 14 Buy 1.2937 23,000 29,755 333,118 12/15/22
Opaleye Management Inc. 10% Owner 10% Owner Dec 06 Sell 1.44 1,539 2,216 4,010,000 12/08/22
THEUER CHARLES President and CEO President and CEO Nov 18 Buy 1.41 13,900 19,599 310,118 11/22/22
THEUER CHARLES President and CEO President and CEO Nov 03 Buy 1.52 9,200 13,984 296,218 11/04/22
THEUER CHARLES President and CEO President and CEO Nov 02 Buy 1.59 6,000 9,540 287,018 11/03/22
Opaleye Management Inc. 10% Owner 10% Owner Oct 18 Buy 1.65 12,500 20,625 4,125,000 10/19/22
THEUER CHARLES President and CEO President and CEO Oct 03 Buy 1.67 5,000 8,350 272,518 10/05/22
Opaleye Management Inc. 10% Owner 10% Owner Sep 29 Buy 1.7415 9,400 16,370 410,000 10/03/22
Opaleye Management Inc. 10% Owner 10% Owner Sep 27 Buy 1.6924 1,700 2,877 400,600 09/28/22
THEUER CHARLES President and CEO President and CEO Sep 22 Buy 1.76 5,000 8,800 267,518 09/26/22
Opaleye Management Inc. 10% Owner 10% Owner Sep 22 Buy 1.73 17,311 29,948 398,900 09/22/22
Opaleye Management Inc. 10% Owner 10% Owner Sep 19 Buy 1.8733 5,000 9,366 375,000 09/19/22
Opaleye Management Inc. 10% Owner 10% Owner Jul 26 Buy 1.72 2,254 3,877 370,000 07/26/22
THEUER CHARLES President and CEO President and CEO Jul 22 Buy 1.85 4,500 8,325 262,518 07/25/22
Opaleye Management Inc. 10% Owner 10% Owner Jul 15 Buy 1.7815 11,826 21,068 367,746 07/15/22
Opaleye Management Inc. 10% Owner 10% Owner Jul 14 Buy 1.8122 7,187 13,024 355,920 07/14/22
THEUER CHARLES President and CEO President and CEO Jul 12 Buy 1.86 6,000 11,160 258,018 07/14/22
Opaleye Management Inc. 10% Owner 10% Owner Jun 24 Buy 1.3919 11,419 15,894 348,733 06/27/22
Opaleye Management Inc. 10% Owner 10% Owner Jun 21 Buy 1.3127 841,989 1,105,279 3,776,589 06/23/22
THEUER CHARLES President and CEO President and CEO May 09 Buy 1.85 10,000 18,500 252,018 05/11/22
Opaleye Management Inc. 10% Owner 10% Owner May 10 Buy 1.76 9,700 17,072 337,314 05/10/22
THEUER CHARLES President and CEO President and CEO May 06 Buy 1.97 2,500 4,925 242,018 05/10/22
THEUER CHARLES President and CEO President and CEO Apr 29 Buy 1.9709 5,000 9,854 239,518 05/03/22
Opaleye Management Inc. 10% Owner 10% Owner Apr 29 Buy 1.98 7,100 14,058 336,114 04/29/22
Opaleye Management Inc. 10% Owner 10% Owner Apr 22 Buy 2.21 52,777 116,637 335,114 04/25/22
THEUER CHARLES President and CEO President and CEO Apr 21 Buy 2.30 4,500 10,350 234,518 04/25/22
Opaleye Management Inc. 10% Owner 10% Owner Apr 13 Buy 2.5 20,041 50,102 330,041 04/14/22
Opaleye Management Inc. 10% Owner 10% Owner Apr 11 Buy 2.45 27,198 66,635 325,000 04/12/22
THEUER CHARLES President and CEO President and CEO Apr 08 Buy 2.50 2,000 5,000 226,518 04/12/22
THEUER CHARLES President and CEO President and CEO Mar 30 Buy 2.70 4,000 10,800 224,518 04/01/22
Brown Scott B. Chief Financial Offi.. Chief Financial Officer Mar 29 Buy 2.82 1,000 2,820 8,628 03/30/22
THEUER CHARLES President and CEO President and CEO Mar 21 Buy 2.45 1,200 2,940 220,518 03/23/22
Opaleye Management Inc. 10% Owner 10% Owner Mar 16 Buy 2.20 2,235 4,917 2,837,735 03/17/22
Opaleye Management Inc. 10% Owner 10% Owner Jan 21 Buy 2.12 52,363 111,010 317,363 01/24/22
Opaleye Management Inc. 10% Owner 10% Owner Dec 29 Buy 2.51 52,325 131,336 305,000 12/29/21
WIGGINS MARK C Chief Business Offic.. Chief Business Officer Dec 30 Buy 10.57 1,000 10,570 13,700 12/30/20
Opaleye Management Inc. 10% Owner 10% Owner Oct 23 Buy 4.4 8,656 38,086 1,797,094 10/23/20
Opaleye Management Inc. 10% Owner 10% Owner Sep 25 Buy 4.64 78,734 365,326 1,785,438 09/25/20